{"entity":{"id":"nct07122414","kind":"trial","name":"A Study of Intravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder Cancer","aka":[],"tldr":"A phase 1/2 trial of FL115 in bladder & urothelial cancer, run by Suzhou Forlong Biotechnology Co., Ltd, now recruiting.","summary":"A Study of Intravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder Cancer is a phase 1/2 interventional study registered as NCT07122414 by Suzhou Forlong Biotechnology Co., Ltd, with 80 participants planned, started 2024-08-16 and due to reach its primary completion in 2027-10-10. Interventions recorded: FL115 and FL115+BCG.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07122414","url":"https://clinicaltrials.gov/study/NCT07122414"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["urothelial"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["suzhou-forlong-biotechnology"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07122414","phase":"1/2","setting":"A Phase I/II, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of Intravesical FL115 Alone or in Combination With BCG in Subjects With Non-Muscle Invasive Bladder Cancer, Including Dose Escalation and Cohort Expansion","sponsor":"Suzhou Forlong Biotechnology Co., Ltd","enrolled":80,"outcomes":[]},"route":"/trials/nct07122414/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"}],"company":[{"id":"suzhou-forlong-biotechnology","kind":"company","name":"Suzhou Forlong Biotechnology","route":"/companies/suzhou-forlong-biotechnology/"}]}}